Izokibep is a small protein that inhibits IL-17A [1]. The compound currently advanced to the assessment of efficacy and safety in moderate-to-severe HS in an ongoing phase 3 trial (NCT05905783). Dr Kim Papp (Probity Medical Research, ON, Canada) presented the results for the primary endpoint of HiSCR75 at week 12.
The study randomised 258 participants (mean age of 37.3 years; 69% women) to placebo or weekly 160 mg of izokibep over 16 weeks. The mean count of abscesses and nodules was 13.4, draining tunnels 2.2, and the Dermatology Life Quality Index (DLQI) was 11.9.
A first statistically significant separation of the HiSCR75 curves was already seen at week 4. At week 12, 33% of participants in the izokibep arm reached HiSCR75 versus 21% on placebo (P<0.05). “I have some real breaking news,” Dr Papp revealed, explaining that he had only moments ago received the official results of HiSCR75 at week 16. “You will see it in the final publication: week 16 38% izokibep, 20% placebo—spectacular results.”
The results of the secondary endpoints HiSCR90 and 100 also favoured izokibep (25% vs 9%; P<0.001 and 22% vs 8%; P<0.01). Further ameliorations were found in patient-reported outcomes like DLQI and skin pain numeric rating scale (Skin Pain-NRS). Of note, half of the baseline Hurley 2 participants attained a count of 0, 1, or 2 for inflammatory lesions (P<0.01).
The interim rate of serious treatment-emergent adverse events was 0.8% on izokibep and 3.1% on placebo. The most common adverse events were injection-site reaction (65.1% vs 7.8%), headache (10.1% vs 9.3%), and nasopharyngitis (7.0% in both groups). No cases of candidiasis were seen in the izokibep arm.
- Papp KA, et al. Efficacy and safety of izokibep, a novel IL-17A inhibitor, in moderate-to-severe hidradenitis suppurativa: Week 12 results from a randomized, double-blind, placebo-controlled, multicentre, phase 3 study. D1T01.2A, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support was provided by Karin Drooff MPH
Posted on
Previous Article
« Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis Next Article
Familial hidradenitis suppurativa associated with higher risk for metabolic disease »
« Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis Next Article
Familial hidradenitis suppurativa associated with higher risk for metabolic disease »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
May 17, 2022
New insights into psoriasis comorbidity
June 21, 2019
Granulomatous rosacea: exploratory histological markers
August 26, 2019
Will malignant melanoma become a curable disease?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com